• linkedin
  • Increase Font
  • Sharebar

    RCC: Multiple pathways provide therapeutic targets

    The current state of targeted therapy and personalized medicine in renal cell carcinoma (RCC) is largely limited to the settings in which drugs were approved (first vs. later line) and the side effect profile of therapeutic agents matched with patient comorbidities, according to a presentation at the Society of Urologic Oncology annual meeting in San Antonio by Toni K. Choueiri, MD.

    Related - High-grade bladder Ca: New data improve risk stratification

    “Folks have worked for the past 15 to 20 years on biomarkers [to predict response to therapies] in metastatic RCC, spanning cytokines (IL2, INF), VEGF-targeted agents, mTOR inhibitors, and PD-1 inhibitors,” explained Dr. Choueiri, of the Lank Center for Genitourinary Oncology at the Dana-Farber Cancer Institute, Boston.

    “Still, nothing is part of an algorithm that is clinically valid for patient care.”

    In his presentation, “Targeted therapies and personalized medicine in kidney cancer,” Dr. Choueiri summarized many of the findings from The Cancer Genome Atlas analysis in clear cell RCC that extend beyond the importance of the VHL mutation (Nature 2013; 499:43-9). Specifically, several genes involved in chromatin regulation (eg, PRBM1, BAP1, SETD2) are frequently mutated, and some, including BAP1, may have prognostic value.

    Furthermore, the metabolic shift in aggressive cancers may provide a potential therapeutic target.

    “While this is a big area of research at several institutions, we have yet to see a drug that can target tumor metabolism in an effective way,” said Dr. Choueiri.

    Also see: Immunotherapies move toward FDA approval for urothelial Ca

    Lastly, genes from the PI3K/Akt/mTOR pathway are also mutated in approximately 20% to 30% of patients. This has led to consideration of genomic alterations in this pathway as potential biomarkers to predict therapeutic response to mTOR inhibitors. In a study conducted at Dana-Farber, mutations in MTOR, TSC1, or TSC2 were more common in responders than non-responders (Clin Cancer Res 2016; 22:2445-52). However, a substantial fraction of responders had no mTOR pathway mutation identified.

    Next: Dr. Choueiri - VEGF "pathway" less defined

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll

    View Results